Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US

Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More